# Great Point Partners LLC 13F holdings Q2 2026: $529 million

Great Point Partners LLC reported $529 million in 13F securities across 42 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Abivax SA at $53.3 million, 10.1% of the reported value. Since Q1 2026 it opened 13 new positions and exited 13.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $529,120,900
- Positions: 42
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1281446
- Form 13F file number: 028-11743
- CRD number: 158423
- Business address: 165 Mason Street, 3rd Floor, Greenwich, CT 06830
- SEC filing: [0001172661-26-003750](https://www.sec.gov/Archives/edgar/data/1281446/000117266126003750/0001172661-26-003750-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/great-point-partners-llc-158423)

## Top 25 holdings by value

The largest of 42 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| Abivax SA | SPONSORED ADS (call) | 400,000 | $53.3 million | New |
| [Vor Biopharma Inc](https://specstream.ai/data/institutional-holders/vor-biopharma-inc-929033207) | COM NEW | 1,700,000 | $31.3 million | -50,000 |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 204,314 | $27.2 million | New |
| Immunitybio Inc | COM (put) | 3,000,800 | $26.3 million | No change |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 600,836 | $25.8 million | +401,488 |
| [Zura Bio LTD](https://specstream.ai/data/institutional-holders/zura-bio-ltd-g9ty5a101) | CLASS A ORD SHS | 4,215,930 | $24.9 million | No change |
| [Alumis Inc](https://specstream.ai/data/institutional-holders/alumis-inc-022307102) | COM | 856,061 | $24.1 million | No change |
| [Sol-Gel Technologies LTD](https://specstream.ai/data/institutional-holders/sol-gel-technologies-ltd-m8694l137) | SHS NEW | 274,363 | $20.3 million | No change |
| Ultragenyx Pharmaceutical in | COM (put) | 600,000 | $20 million | New |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 425,000 | $20 million | New |
| [Annexon Inc](https://specstream.ai/data/institutional-holders/annexon-inc-03589w102) | COM | 3,500,000 | $20 million | +1,000,000 |
| [Oruka Therapeutics Inc](https://specstream.ai/data/institutional-holders/oruka-therapeutics-inc-687604108) | COM | 183,330 | $17.4 million | No change |
| [Moonlake Immunotherapeutics](https://specstream.ai/data/institutional-holders/moonlake-immunotherapeutics-61559x104) | CLASS A ORD | 855,813 | $16.7 million | +355,813 |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 2,029,933 | $15.7 million | New |
| [Contineum Therapeutics Inc](https://specstream.ai/data/institutional-holders/contineum-therapeutics-inc-21217b100) | CL A | 921,481 | $15.1 million | +121,283 |
| [Immix Biopharma Inc](https://specstream.ai/data/institutional-holders/immix-biopharma-inc-45258h106) | COM | 1,277,642 | $13.2 million | +927,642 |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 1,000,000 | $13 million | -334,130 |
| [Amylyx Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/amylyx-pharmaceuticals-inc-03237h101) | COM | 700,000 | $12.6 million | -1,050,000 |
| [Nektar Therapeutics](https://specstream.ai/data/institutional-holders/nektar-therapeutics-640268306) | COM NEW | 175,000 | $12.2 million | -141,453 |
| [Neurogene Inc](https://specstream.ai/data/institutional-holders/neurogene-inc-64135m105) | COM | 352,180 | $11.1 million | -147,820 |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 317,221 | $10.3 million | +17,221 |
| [Opus Genetics Inc](https://specstream.ai/data/institutional-holders/opus-genetics-inc-67577r102) | COM | 1,970,187 | $8.1 million | +1,645,847 |
| [Eupraxia Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/eupraxia-pharmaceuticals-inc-29842p105) | COM | 1,200,000 | $7.9 million | No change |
| [Bright Minds Biosciences Inc](https://specstream.ai/data/institutional-holders/bright-minds-biosciences-inc-10919w405) | COM NEW | 109,603 | $7.7 million | -110,397 |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 3,046,557 | $6.8 million | New |

## New positions in Q2 2026

13 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Abivax SA | SPONSORED ADS (call) | 400,000 | $53.3 million |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 204,314 | $27.2 million |
| Ultragenyx Pharmaceutical in | COM (put) | 600,000 | $20 million |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 425,000 | $20 million |
| [Sagimet Biosciences Inc](https://specstream.ai/data/institutional-holders/sagimet-biosciences-inc-786700104) | COM SER A | 2,029,933 | $15.7 million |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 3,046,557 | $6.8 million |
| [Jatt II Acquisition Corp](https://specstream.ai/data/institutional-holders/jatt-ii-acquisition-corp-g50765109) | ORD SHS | 500,000 | $5.7 million |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 1,741,232 | $5.3 million |
| [Amanat Acquisition Corp](https://specstream.ai/data/institutional-holders/amanat-acquisition-corp-g0375m101) | CL A ORD | 500,000 | $5.1 million |
| [Scynexis Inc](https://specstream.ai/data/institutional-holders/scynexis-inc-811292309) | COM | 944,292 | $3.8 million |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 70,000 | $3.6 million |
| [Rein Therapeutics Inc](https://specstream.ai/data/institutional-holders/rein-therapeutics-inc-00887a204) | COM NEW | 2,575,000 | $2.7 million |
| [DBV Technologies S a](https://specstream.ai/data/institutional-holders/dbv-technologies-s-a-23306j309) | SPONSORED ADS | 156,906 | $2.6 million |

## Positions exited in Q2 2026

13 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Apogee Therapeutics Inc](https://specstream.ai/data/institutional-holders/apogee-therapeutics-inc-03770n101) | COM | 374,000 | $31.5 million |
| Kalvista Pharmaceuticals Inc | COM | 675,000 | $13.6 million |
| [Immunovant Inc](https://specstream.ai/data/institutional-holders/immunovant-inc-45258j102) | COM | 545,625 | $13.6 million |
| [Jade Biosciences Inc](https://specstream.ai/data/institutional-holders/jade-biosciences-inc-008064206) | COM NEW | 964,462 | $13.6 million |
| [Zenas Biopharma Inc](https://specstream.ai/data/institutional-holders/zenas-biopharma-inc-98937l105) | COM | 524,066 | $10.2 million |
| [Compass Therapeutics Inc](https://specstream.ai/data/institutional-holders/compass-therapeutics-inc-20454b104) | COM | 1,350,000 | $7.1 million |
| Scynexis Inc | COM NEW | 7,554,347 | $6.9 million |
| [Context Therapeutics Inc](https://specstream.ai/data/institutional-holders/context-therapeutics-inc-21077p108) | COM | 2,238,496 | $5.9 million |
| [Unicycive Therapeutics Inc](https://specstream.ai/data/institutional-holders/unicycive-therapeutics-inc-90466y202) | COM NEW | 796,558 | $5.2 million |
| [Tenax Therapeutics Inc](https://specstream.ai/data/institutional-holders/tenax-therapeutics-inc-88032l605) | COM NEW | 327,307 | $5.2 million |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 82,800 | $2.3 million |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 124,666 | $1.9 million |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 50,000 | $1.8 million |

## Also on SpecStream

- [Great Point Partners LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1281446/000117266126003750/0001172661-26-003750-index.htm)
- [Great Point Partners LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/great-point-partners-llc-158423)
- [Largest 13F filers in Connecticut](https://specstream.ai/data/institutional-holdings/state/connecticut)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Greenwich, Connecticut

- [Investment management firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/investment-management-firms/greenwich-connecticut-united-states)
- [Interior design firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/interior-design-firms/greenwich-connecticut-united-states)
- [Financial services firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/financial-services-firms/greenwich-connecticut-united-states)
- [Financial advisory firms in Greenwich, Connecticut](https://specstream.ai/data/businesses/financial-advisory-firms/greenwich-connecticut-united-states)
- [Contractors in Greenwich, Connecticut](https://specstream.ai/data/businesses/contractors/greenwich-connecticut-united-states)
- [Banks and credit unions in Greenwich, Connecticut](https://specstream.ai/data/businesses/banks-and-credit-unions/greenwich-connecticut-united-states)
